Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 9/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.33 |
| ▸ | POLB | P06746 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | NPY1R | P25929 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17162692 | 0.89 | P2RX7 (0.38) | P2RX7MAPK1KMT2AALDH1A1OPRM1 | |
| SCHEMBL29989231 | 0.89 | P2RX7 (0.38) | P2RX7MAPK1KMT2AALDH1A1OPRM1 | |
| SCHEMBL21080 | 0.81 | P2RX7 (0.41) | P2RX7MAPK1MEN1KMT2AOPRM1 | |
| SCHEMBL17850040 | 0.81 | P2RX7 (0.41) | P2RX7MAPK1MEN1KMT2AOPRM1 | |
| SCHEMBL22668 | 0.81 | P2RX7 (0.33) | P2RX7MAPK1KMT2APOLBLMNA | |
| SCHEMBL17178005 | 0.80 | P2RX7 (0.35) | P2RX7MAPK1 | |
| SCHEMBL17178006 | 0.80 | P2RX7 (0.35) | P2RX7MAPK1 | |
| SCHEMBL20673643 | 0.79 | DDB1 (0.37) | MAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL15166801 | 0.79 | P2RX7 (0.41) | P2RX7MAPK1MEN1KMT2AOPRM1 | |
| SCHEMBL22898175 | 0.78 | CTDSP1 (0.38) | MAPK1MEN1KMT2APOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200360404-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360404-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CYP8B1, LSS | P2RX7 3047/4885MAPK1 2233/4885MEN1 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.